山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (10): 77-81.doi: 10.6040/j.issn.1671-7554.0.2021.0771
高金梅1,黄映波2,冯珍珍3
GAO Jinmei1, HUANG Yingbo2, FENG Zhenzhen3
摘要: 目的 评估单核细胞趋化蛋白-1(MCP-1)在全身炎症反应综合征(SIRS)中的诊断价值。 方法 前瞻性研究。收集天津医科大学第二医院重症监护病房(ICU)、泌尿外科及胃肠外科于2020年8月至2021年4月收住院的67例经诊断符合SIRS的患者作为病例组,对照组为同期体检人员44例。采用酶联免疫吸附法(ELISA)检测病例组与对照组血清中的MCP-1浓度并比较其差异。将病例组按是否存在多器官功能障碍(MODS)分为MODS组(n=26)和非MODS组(n=41),比较血清MCP-1浓度,绘制受试者工作曲线,评价血清MCP-1对SIRS伴MODS的诊断效能。根据患者临床表现及检测结果,将患者分为脓毒症组(n=15)和非脓毒症组(n=52),比较两组间血清MCP-1浓度。 结果 SIRS患者血清MCP-1中位水平为180.2(90.9~407.4)pg/mL,对照组血清中位水平为53.4(40.2~83.7)pg/mL(P<0.001)。SIRS患者中MODS组血清MCP-1中位水平为426.2(150.1~733.6)pg/mL,非MODS组血清MCP-1中位水平为135.0(55.6~236.1)pg/mL(P<0.001),以血清MCP-1为变量对SIRS伴MODS诊断效能的ROC曲线下面积为0.74,最大约登指数对应的血清MCP-1临界值为176.0 pg/mL,敏感度为76.9%,特异性为65.9%。脓毒症组与非脓毒症组血清MCP-1比较差异无统计学意义(P=0.832)。 结论 SIRS患者血清MCP-1检测对MODS具有辅助诊断价值,但不能作为SIRS进展为脓毒症的预测指标。
中图分类号:
[1] Oh H, Bae E, Lim S, et al. Temporal changes in physiological parameters of systemic inflammatory response syndrome during the three days prior to a diagnosis of sepsis: a case-control study [J]. Clin Nurs, 2016, 25(21-22): 3176-3188. [2] Staubli SM, Schäfer J, Rosenthal R, et al. The role of CRP and Pentraxin 3 in the prediction of systemic inflammatory response syndrome and death in acute pancreatitis [J]. Sci Rep, 2019, 9(1): 18340. doi: 10.1038/s41598-019-54910-8. [3] Shafik S, Mallick S, Fogel J, et al. The utility of systemic inflammatory response syndrome(SIRS)for diagnosing sepsis in the immediate postpartum period [J]. J Infect Public Health, 2019, 12(6): 799-802. [4] Kaukonen KM, Bailey M, Pilcher D, et al. The systemic inflammatory response syndrome criteria and their differential association with mortality [J]. J Crit Care, 2018, 8(46): 29-36. [5] Jacome T, Tatum D. Systemic inflammatory response syndrome(SIRS)score independently predicts poor outcome in isolated traumatic brain injury [J]. Neurocrit Care, 2018, 28(1): 110-116. [6] Selsted ME, Brown DM, DeLange RJ, et al. Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages [J]. J Biol Chem, 1983, 258(23): 14485-14489. [7] Gruber HE, Hoelscher GL, Ingram JA, et al. Proinflammatory cytokines modulate the chemokine CCL2(MCP-1)in human annulus cells in vitro: CCL2 expression and production [J]. Exp Mol Pathol, 2015, 98(1): 102-105. [8] Chen ZY, Wang XY, Yang YM, et al. LncRNA SNHG16 promotes colorectal cancer cell proliferation, migration, and epithelial-mesenchymal transition through miR-124-3p/MCP-1 [J]. Gene Ther, 2020, 28. doi: 10.1038/s41434-020-0176-2. [9] Hu Q, Myers M, Fang W, et al. Role of ALDH1A1 and HTRA2 expression in CCL2/CCR2-mediated breast cancer cell growth and invasion [J]. Biol Open, 2019, 8(7): bio040873. doi: 10.1242/bio.040873. [10] Martinovic I, Abegunewardene N, Seul M, et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease [J]. Circ J, 2005, 69(12): 1484-1489. [11] Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia [J]. Cytokine Growth Factor Rev, 2020, 53: 38-42. doi: 10.1016/j.cytogfr.2020.04.002. [12] Cavaillon JM, Giamarellos-Bourboulis EJ. Immunosuppression is inappropriately qualifying the immune status of septic and SIRS patients [J]. Shock, 2019, 52(3): 307-317. [13] Zhu T, Liao X, Feng T, et al. Plasma monocyte chemoattractant protein 1 as a predictive marker for sepsis prognosis: a prospective cohort study [J]. Tohoku J Exp Med, 2017, 241(2): 139-147. [14] Li YT, Wang YC, Lee HL, et al. Monocyte chemoattractant protein-1, a possible biomarker of multiorgan failure and mortality in ventilator-associated pneumonia [J]. Int J Mol Sci, 2019, 20(9): 2218. doi: 10.3390/ijms20092218. [15] Gaski GE, Metzger C, McCarroll T, et al. Early Immunologic response in multiply injured patients with orthopaedic injuries is associated with organ dysfunction [J]. J Orthop Trauma, 2019, 33(5): 220-228. doi: 10.1097/BOT.0000000000001437. [16] 罗惠君, 张卫星, 陈晶莹, 等. 血清TSLP、炎症因子水平与脓毒症患者预后的相关性分析[J]. 中国医学创新, 2020, 17(9): 1-4. LUO Huijun, ZHANG Weixing, CHEN Jingying, et al. Correlation between serum TSLP, inflammatory factors levels and prognosis in sepsis patients [J]. Medical Innovation of China, 2020, 17(9): 1-4. [17] Jain S, Midha S, Mahapatra SJ, et al. Interleukin-6 significantly improves predictive value of systemic inflammatory response syndrome for predicting severe acute pancreatitis [J]. Pancreatology, 2018, 18(5): 500-506. [18] 杨珍, 张艳敏, 王倩倩, 等. 微小RNA-103 及RNA-107表达与120例脓毒症患者临床特征及预后的关联分析[J]. 山东大学学报(医学版),2020, 58(12): 77-85. YANG Zhen, ZHANG Yanmin, WANG Qianqian, et al. Correlations of microRNA-103 and microRNA-107 expressions with the clinical characteristics and prognosis of 120 cases of sepsis [J]. Journal of Shandong University(Health Sciences), 2020, 58(12): 77-85. [19] Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? [J]. J Clin Invest, 2016, 126(1): 23-31. [20] Peters van Ton AM, Kox M, Abdo WF, et al. Precision immunotherapy for sepsis [J]. Front Immunol, 2018, 5(9): 1926. doi: 10.3389/fimmu.2018.01926. eCollection 2018. [21] Wang Y, Liu Q, Liu T, et al. Early plasma monocyte chemoattractant protein 1 predicts the development of sepsis in trauma patients: A prospective observational study [J]. Medicine(Baltimore), 2018, 97(14): e0356. doi:10.1097/MD. 0000000000010356. [22] Spoto S, Fogolari M, De Florio L, et al. Procalcitonin and MR-proAdrenomedullin combination in the etiological diagnosis and prognosis of sepsis and septic shock [J]. Microb Pathog, 2019, 137: 103763. doi: 10.1016/j.micpath. [23] Lvovschi V, Arnaud L, Parizot C, et al. Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department: a prospective observational study [J]. PLoS One, 2011, 6(12): e28870. doi: 10.1371/journal.pone.0028870. |
[1] | 江勇,宋剑刚,朱大侠,刘礼剑. 柚皮素通过调控巨噬细胞NLRP3炎症小体活化对脓毒症致急性肺损伤的影响[J]. 山东大学学报 (医学版), 2021, 59(1): 14-21. |
[2] | 杨珍,张艳敏,王倩倩,陈惠敏,冯强,周少英. 微小RNA-103及RNA-107表达与120例脓毒症患者临床特征及预后的关联分析[J]. 山东大学学报 (医学版), 2020, 58(12): 77-85. |
[3] | 刘晓,刘志广,范志松,王媛,杨兴肖,孔洁羽,陈俊卓,刘俊霞. 严重脓毒症与脓毒性休克患者预后分析[J]. 山东大学学报(医学版), 2016, 54(10): 80-84. |
[4] | 郑加田,朱凯,孙红胜,付敏,潘正论. IL-18和MCP-1基因多态性与类风湿关节炎易感性关系的Meta分析[J]. 山东大学学报(医学版), 2014, 52(6): 98-104. |
[5] | 吴学田,王坤,孙树栋. PAI-1基因多态性与烧伤脓毒症的相关性[J]. 山东大学学报(医学版), 2014, 52(6): 105-107. |
[6] | 张庆伟1,王春亭2,王启志2,张琳2,王鹏2,孟玫2. 丙酮酸乙酯对脓毒症大鼠小肠黏膜屏障的保护作用及其机制[J]. 山东大学学报(医学版), 2014, 52(5): 30-34. |
[7] | 刘新农,展翰翔,胡三元,张光永, 王磊. 血清miR-146a在脓毒症早期诊断中的价值[J]. 山东大学学报(医学版), 2013, 51(9): 92-94. |
[8] | 白霄1,宋光民1,王维2,赵鑫1,赵宏磊1,赵文杰1,张健1. 单核细胞趋化蛋白-1和NF-κB通路在心脏移植排斥反应中的作用[J]. 山东大学学报(医学版), 2013, 51(11): 1-5. |
[9] | 唐琳娜,吴大玮,杨洁,卢海宁,张帆,韩辉,郭海鹏. 不同剂量地塞米松对脓毒症小鼠肺组织糖皮质激素受体-α表达及肺损伤的影响[J]. 山东大学学报(医学版), 2013, 51(10): 19-23. |
[10] | 卢海宁,陈晨,吴大玮,吴玉霞,彭苗苗,杨洁,唐琳娜,郭海鹏. 尿胰蛋白酶抑制剂对脓毒症大鼠早期肺损伤的保护作用[J]. 山东大学学报(医学版), 2012, 50(9): 15-. |
[11] | 李文元,丁士芳. 急性呼吸窘迫综合征患者预后的危险因素分析[J]. 山东大学学报(医学版), 2012, 50(3): 93-. |
[12] | 王焕亮1,2,岳寿伟2,徐迎雪1,荣菲1,类维富1,张文华3. 利多卡因对脓毒症大鼠肾组织高迁移率族蛋白表达的影响[J]. 山东大学学报(医学版), 2011, 49(11): 21-. |
[13] | 徐晖1,张萍1,吴学忠2,张爱荣1. 卵巢上皮性肿瘤MCP-1基因表达的研究[J]. 山东大学学报(医学版), 2010, 48(1): 94-. |
[14] | 刘粉叶,张继东,胡连海,来丽萍,杨发林 . 益肾活血胶囊对同型半胱氨酸致兔动脉粥样硬化MCP-1mRNA表达及NF-κB活化的影响[J]. 山东大学学报(医学版), 2008, 46(4): 353-356. |
[15] | 吴玉生,张道杰,李建军,付崇健 . 解毒化瘀方对脓毒症大鼠蛋白C-mRNA表达及血浆蛋白C活性的影响[J]. 山东大学学报(医学版), 2008, 46(4): 382-384. |
|